Online sexual enhancement products risky: FDA

	Tweet

Some sexual enhancement products sold on the Internet contain the same ingredients as prescription drugs such as Viagra and are not only illegal but also dangerous, the U.S. Food and Drug Administration cautioned on Wednesday.

Erectile dysfunction products can cause a deadly interaction with many heart drugs, notably those containing nitrates.

“The U.S. Food and Drug Administration is warning consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4EVERON,” the agency said in a statement.

"These products threaten the public health because they contain undeclared chemicals that are similar or identical to the active ingredients used in several FDA-approved prescription drug products,” added Dr. Steven Galson, Director of the FDA’s Center for Drug Evaluation and Research.

“This risk is even more serious because consumers may not know that these ingredients can interact with medications and dangerously lower their blood pressure.”

Zimaxx contains sildenafil, the active pharmaceutical ingredient in Viagra, Pfizer’s prescription erectile dysfunction product.

The other products contain chemical ingredients that are similar either to sildenafil or to vardenafil, the active ingredient in Levitra. Levitra is a prescription erectile dysfunction drug developed and sold jointly by Bayer AG, GlaxoSmithKline Plc and Schering-Plough Corp..

“Consumers with diabetes, High Blood Pressure, High cholesterol, or heart disease often take nitrates,” the FDA said.

“ED (erectile dysfunction) is a common problem in men with these conditions, and they may seek products like the ones noted above because these products claim that they are ‘all natural’ or that they do not contain the active ingredients used in FDA-approved ED drugs.”

The agency said it had stopped a shipment of 4EVERON from entry to the United States and warned the companies selling the drugs.

RELATED STORIES:
Meridia aids weight loss and diabetes control   U.S. says J&J arthritis drug promotion misleading   ADHD drug use in US rose among ages 20-44: study   Memantine cost-effective for severe Alzheimer’s   Remicade improves diabetes-related eye condition   Measures how to clamp down on Internet pharmacies   Cautious Optimism for New Alzheimer’s Medications   FDA stands by safety of approved drugs   FDA advisory panel recommends adding warning label to Tamoxifen   UK lawmakers slam slack pharmaceutical regulation   Antioxidants may protect against Rocky Mountain spotted fever and other tick-borne illness   Hib vaccines act differently in old and young

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]